AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +55

AbbVie stock closes at USD 265.21 as EU approval adds support

Drug approval Earnings report AI-generated analysis

📈 AbbVie stock closed at USD 265.21 on the NYSE, up 0.3 percent, with a market cap of approximately USD 469.10 billion.

💰 Q2 2026 revenue surged 10.2 percent year over year to USD 16.99 billion, significantly beating consensus estimates.

📊 EPS for the quarter reached USD 3.65, surpassing analyst expectations of USD 3.61 and showing strong growth from the prior year.

✅ The European Commission granted approval for RINVOQ in pediatric arthritis, expanding the drug's commercial potential.

🔮 AbbVie issued Q3 2026 adjusted EPS guidance between USD 3.84 and USD 3.88, providing clear forward-looking targets.

📉 The stock traded near its 52-week high of USD 267.47 but remained slightly below the peak at close.

🎯 Analysts maintain a Moderate Buy rating with an average price target of USD 276.64, indicating potential upside.

Bullish Signals
  • AbbVie reported Q2 revenue of USD 16.99 billion, representing a robust 10.2 percent year-over-year increase that significantly exceeded analyst consensus.
  • The company beat EPS estimates with results of USD 3.65 versus the expected USD 3.61, demonstrating strong operational performance.
  • AbbVie received European Commission approval for RINVOQ in pediatric arthritis, adding a valuable new indication to its immunology portfolio.
  • The company provided clear Q3 2026 adjusted EPS guidance ranging from USD 3.84 to USD 3.88, signaling confidence in near-term earnings.
Full Analysis
AbbVie Inc. closed its shares at USD 265.21 on the NYSE on September 22, 2026, marking a modest 0.3 percent gain. The company reported strong second-quarter financial results with revenue rising 10.2 percent year over year to USD 16.99 billion and earnings per share (EPS) reaching USD 3.65, which beat analyst consensus estimates of USD 3.61 for EPS and USD 16.80 billion for revenue. A significant regulatory milestone occurred when the European Commission approved RINVOQ for pediatric arthritis, adding a new indication to AbbVie's immunology portfolio. This approval is viewed as a concrete commercial step toward diversifying growth beyond its evolving portfolio, although the immediate market reaction was limited to a small daily price increase despite the stock trading near its yearly high. Looking ahead, AbbVie provided adjusted EPS guidance for the third quarter of 2026 ranging between USD 3.84 and USD 3.88. Analysts maintain a Moderate Buy rating with an average price target of USD 276.64, suggesting potential upside from the current closing price. The company's market capitalization stands at approximately USD 469.10 billion as of September 22, 2026.